aTyr Pharma Inc
471A
Company Profile
Business description
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Contact
10240 Sorrento Valley Road
Suite 300
San DiegoCA92121
USAT: +1 858 731-8389
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,076.80 | 28.00 | 0.31% |
| CAC 40 | 8,045.80 | 121.93 | -1.49% |
| DAX 40 | 23,815.75 | 389.61 | -1.61% |
| Dow JONES (US) | 47,954.74 | 784.67 | -1.61% |
| FTSE 100 | 10,413.94 | 153.71 | -1.45% |
| HKSE | 25,578.57 | 257.23 | 1.02% |
| NASDAQ | 22,748.99 | 58.50 | -0.26% |
| Nikkei 225 | 55,490.04 | 211.98 | 0.38% |
| NZX 50 Index | 13,520.93 | 96.96 | -0.71% |
| S&P 500 | 6,830.71 | 38.79 | -0.56% |
| S&P/ASX 200 | 8,845.50 | 20.30 | 0.23% |
| SSE Composite Index | 4,113.37 | 4.80 | 0.12% |